Abstract Library

#2826 NET-02: A Phase II Trial of Liposomal Irinotecan (nal-IRI) and 5-Fluorouracil (5-FU)/Folinic Acid or Docetaxel as Second-Line Therapy in Patients (pts) with Progressive Poorly Differentiated Extra-Pulmonary Neuroendocrine Carcinoma (PD-EP-NEC)

Introduction: The prognosis for pts with PD-EP-NEC is poor.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: McNamara M

Authors: McNamara M, Swain J, Craig Z, Wadsley J, Wall L,

Keywords: poorly differentiated, neuroendocrine carcinoma, second line treatment, docetaxel, liposomal irinotecan, 5-fluorouracil,

#1925 SSA-, H1, H2- and Leukotriene Receptor Blockade Eliminates Handicapping Symptoms from Atypical Carcinoid Syndrome

Introduction: The patient is a female, 59 yrs , previously healthy except from mild allergic rinitis since 12 years of age and at 49 a suspected anaphylaxis after hazelnut intake.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Linder Ekberg K, Dahlén S, Wheelock C, Kolmert J, Bood J,

Keywords: PGD2,

#1704 Diffusion Weighted Imaging as a Screening Tool in the Detection and Monitoring of Pancreatic Neuroendocrine Tumours in Patients with Familial Cancer Syndromes.

Introduction: Pancreatic neuroendocrine tumours (PNETs) occur at a higher frequency and at a younger age in patients with certain genetic conditions e.g. Von Hippel Lindau and Multiple Endocrine Neoplasia type 1. Screening for early detection and monitoring growth rates of PNETs in these high risk patients is vital in their management. MRI has emerged as the gold standard for imaging the pancreas for the detection of PNETs and diffusion weighted imaging (DWI) has become an invaluable adjunct.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Jenkins C, Thomas W, Parry C, Khan M, Owen R,

Keywords: PNET, MRI, VHL, MEN1,